BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $ONC readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04170283-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zanubrutinib readout (P3) · BeOne Medicines $ONC
DESCRIPTION:A Study to Evaluate Long-term Safety of Zanubrutinib Regimens i
 n Participants With B-Cell Malignancies Who Participated in BeiGene Parent
  Studies of Zanubrutinib\n\nPrimary completion date: 2026-12-31 (estimated
 )\nOriginally planned: 2024-12 (+25.0 months)\nPhase 3 · Oncology · B-ce
 ll Malignancies\nEnrollment: 955 · Sites: 153\n\nPrimary completion = las
 t participant's primary-endpoint data collected\; topline results usually 
 follow weeks to months later. Sponsor-reported\, often an estimate. Not in
 vestment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT04170
 283\nhttps://clinicaltrials.gov/study/NCT04170283
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04170283
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03967977-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab readout (P3) · BeiGene $ONC
DESCRIPTION:Study of Tislelizumab in Combination With Chemotherapy Compared
  to Chemotherapy Alone for Participants With Urothelial Carcinoma\n\nPrima
 ry completion date: 2027-06-30 (estimated)\nOriginally planned: 2022-07 (+
 60.0 months)\nPhase 3 · Oncology · Urothelial Carcinoma\nEnrollment: 420
  · Sites: 46\n\nPrimary completion = last participant's primary-endpoint 
 data collected\; topline results usually follow weeks to months later. Spo
 nsor-reported\, often an estimate. Not investment advice.\n\nhttps://trial
 sonar.netlify.app/radar.html?nct=NCT03967977\nhttps://clinicaltrials.gov/s
 tudy/NCT03967977
URL:https://trialsonar.netlify.app/radar.html?nct=NCT03967977
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05707377-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~ALMOND readout (P2/3) · BeOne Medicines $ONC
DESCRIPTION:A Study to Examine the Efficacy and Safety of Zanubrutinib Give
 n to Adults With Primary Membranous Nephropathy\n\nPrimary completion date
 : 2027-10 (estimated) — month only\, shown on the 1st\nOriginally planne
 d: 2028-12 (-14.0 months)\nPhase 2/3 · GI·Renal·Heme · Primary Membran
 ous Nephropathy\nEnrollment: 178 · Sites: 45\n\nPrimary completion = last
  participant's primary-endpoint data collected\; topline results usually f
 ollow weeks to months later. Sponsor-reported\, often an estimate. Not inv
 estment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT057073
 77\nhttps://clinicaltrials.gov/study/NCT05707377
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05707377
CATEGORIES:GI·Renal·Heme,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043400-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Subcutaneous Tislelizumab readout (P3) · BeOne Medicines $ONC
DESCRIPTION:A Study to Investigate Tislelizumab Administered as Subcutaneou
 s Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With
  Unresectable or Metastatic Gastric or Gas…\n\nPrimary completion date: 
 2027-10-30 (estimated)\nPhase 3 · Oncology · Metastatic Gastric Adenocar
 cinoma\, Gastroesophageal Junction Adenocarcinoma\nEnrollment: 351 · Site
 s: 95\n\nPrimary completion = last participant's primary-endpoint data col
 lected\; topline results usually follow weeks to months later. Sponsor-rep
 orted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.ne
 tlify.app/radar.html?nct=NCT07043400\nhttps://clinicaltrials.gov/study/NCT
 07043400
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07043400
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
